Dr. Ni is a cell and gene therapy leader with 25+ years of product development experience and deep expertise in CAR-T CMC across early and late stages. She pioneered allogeneic CAR-T product development, including first-in-human allo CAR-T IND approval, and first demonstrated TCR+ cell depleted allo CAR-T products not causing GVHD. Dr. Ni has held senior leadership positions at Pfizer, Allogene, and Gracell, with strong expertise in process development, analytical development, and CMC regulatory strategy.